Stark difference seen in rescheduling of missed test, procedure, or operation by vaccination status
Subsequent Vaccination Cuts Risk for COVID-19 Reinfection
Vaccine effectiveness estimated at 82 percent for those aged 16 to 64 years, 60 percent for those aged 65 years or older
Vaccine Effectiveness Lower for Teens With Predominant Omicron
VE increased for adolescents aged 16 to 17 years at seven or more days after a third booster dose during omicron predominance
Homologous Pfizer-BioNTech Booster Safe for Adolescents
Reactions to booster occur with similar frequency as after receipt of second vaccine dose, generally mild to moderate
White House Unveils New COVID-19 Response Strategy
Program to boost research into ‘long COVID’ has also been announced